Fatih M Uckun

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 15

Top Topics

Ejection Fraction

Multiple Myeloma

Transforming Growth Factor

Top Venues

International journal of molecular sciences

Journal of personalized medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Fatih M Uckun, Sanjive Qazi
Upregulated Expression of ERBB2/HER2 in Multiple Myeloma as a Predictor of Poor Survival Outcomes. International journal of molecular sciences 24 (12) (2023)
Fatih M Uckun, Sanjive Qazi, Vuong Trieu
High Intra-Tumor Transforming Growth Factor Beta 2 Level as a Predictor of Poor Treatment Outcomes in Pediatric Diffuse Intrinsic Pontine Glioma. Cancers 15 (6) (2023)
Fatih M Uckun, Sanjive Qazi, Vuong Trieu
High Intra-Tumor Transforming Growth Factor Beta 2 Level as a Predictor of Poor Treatment Outcomes in Pediatric Diffuse Intrinsic Pontine Glioma. Cancers 15 (6) (2023)
Fatih M Uckun, Sanjive Qazi
Upregulated Expression of ERBB2/HER2 in Multiple Myeloma as a Predictor of Poor Survival Outcomes. International journal of molecular sciences 24 (12) (2023)
Sanjive Qazi, Fatih M Uckun
Upregulated Expression of ErbB1 in Diffuse Large B-Cell Lymphoma as a Predictor of Poor Overall Survival Outcome. Journal of personalized medicine 13 (5) (2023)
Sanjive Qazi, Fatih M Uckun
CD22 Exon 12 Deletion as an Independent Predictor of Poor Treatment Outcomes in B-ALL. Cancers 15 (5) (2023)
Fatih M Uckun, Sanjive Qazi
Upregulated Expression of ERBB2/HER2 in Multiple Myeloma as a Predictor of Poor Survival Outcomes. International journal of molecular sciences 24 (12) (2023)
Sanjive Qazi, Fatih M Uckun
CD22 Exon 12 Deletion as an Independent Predictor of Poor Treatment Outcomes in B-ALL. Cancers 15 (5) (2023)
Fatih M Uckun, Sanjive Qazi
ERBB1/EGFR and JAK3 Tyrosine Kinases as Potential Therapeutic Targets in High-Risk Multiple Myeloma. Onco 2 (4) (2022)
Fatih M Uckun, Muhammad Saeed, Mustafa Awili, Ibrahim H Ozercan, Sanjive Qazi, Cynthia Lee, Adeel Shibli, Alan W Skolnick, Alonso Prusmack, Joseph Varon, Cesar Ip Barrera, Cemal Orhan, Michael Volk, Kazım Şahin
Evaluation of the potential of Rejuveinix plus dexamethasone against sepsis. Future microbiology 17 (2022)
Deniz Can Guven, Taha Koray Sahin, Serkan Akın, Fatih M Uckun
SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research. The oncologist 27 (11) (2022)
Deniz C Guven, Taha K Sahin, Serkan Akın, Fatih M Uckun
Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination. The oncologist 27 (4) (2022)
Fatih M Uckun, Tara L Lin, Alice S Mims, Prapti Patel, Cynthia Lee, Anoush Shahidzadeh, Paul J Shami, Elizabeth Cull, Christopher R Cogle, Justin Watts
A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. Cancers 13 (16) (2021)
Fatih M Uckun
Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma. Cancers 13 (9) (2021)
Fatih M Uckun, Justin Watts, Alice S Mims, Prapti Patel, Eunice Wang, Paul J Shami, Elizabeth Cull, Cynthia Lee, Christopher R Cogle, Tara L Lin
Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436. Cancers 13 (21) (2021)